Report
EUR 193.80 For Business Accounts Only

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.
Underlying
DBV Technologies SA

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.

Provider
EthiFinance
EthiFinance

​EthiFinance is a CSR rating and consulting agency. We accompany investors and companies in the management of risks and opportunities related to sustainable development. We offer investors ESG (Environment, Social, Governance) analyses of issuers, as well as other services. Created in 2004, EthiFinance has become a European leader in the rating of small and medium-sized companies, listed or non-listed.

Other Reports on these Companies
Other Reports from EthiFinance

ResearchPool Subscriptions

Get the most out of your insights

Get in touch